Over the years, marine algae species offer a biological diversity in discovery-phase of new strategy for treatment of several diseases. Interest in seaweed has been on the rise, owing to the recognition of important bioactive molecules. The present study was constructed to explore the potential effectiveness of two species of brown marine algae
Cystoseira myrica and
Padina pavonica in regression of liver fibrosis in the experimental model. Treatment of liver fibrosis bearing rats with either fresh or dry methanolic extract of
Cystoseira myrica and
Padina pavonica revealed significant suppression of liver fibrosis. This finding was evidenced by the decreased urinary lamnine, and 8-Hydroxydeoxyguanosine (8-OHdG) levels, as well as hepatic malondialdehyde (MDA) content, serum hepatocyte growth factor (HGF), nuclear factor kappa-B (NF κB) and interleukin 8 (IL-8) levels, in concomitant with the increased hepatic paraxonase-1(PON-1) activity. Additionally,
Cystoseira myrica and
Padina pavonica extracts could downregulate the expression of Bcl2, KI-67 and transforming growth factor- β (TGF-β) in the liver of the treated rats as documented
via immunohistochemical examination. These encouraging results provide new concepts for the development of natural therapeutic opportunities from brown marine algae in the management of liver fibrosis through their antioxidant, anti-inflammatory and antiproliferative activity.
Abstract Online: 31-August-2015